Summary:
AMP is a multi-site, international phase 2b clinical trial being conducted in partnership by the HIV Vaccine Trials Network and the HIV Prevention Trials Network to determine the safety and effectiveness of VRC01, an antibody found to be particularly effective at neutralizing HIV. Participants will be randomized (assigned by chance) to a control group, which receives a placebo, or the intervention group, which receives the study drug. The drug will be administered by intravenous (IV) infusion.
Qualified Participants Must:
• Be a male
•
Have sex with men or be transgender (MTF & FTM)
•
Be between 18 and 50 years of age
•
Be HIV-negative
•
Be in good health
Qualified Participants May Receive:
$50 for Screening, Consent, and Follow-Up visits.
$100 for Infusion visits.